E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Esophageal squamous cell carcinoma |
|
E.1.1.1 | Medical condition in easily understood language |
Esophageal squamous cell carcinoma occurs most often in the upper and middle portions of the esophagus. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055476 |
E.1.2 | Term | Esophageal squamous cell carcinoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the efficacy of tiragolumab + atezolizumab compared with double placebo on the basis of investigator (INV) assessed progression free survival and overall survival • To evaluate the efficacy of placebo + atezolizumab compared with double placebo on the basis of overall survival. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the efficacy of placebo + atezolizumab compared with double placebo on the basis of INV assessed progression-free survival • To evaluate the efficacy of tiragolumab + atezolizumab versus placebo + atezolizumab • To evaluate the efficacy of tiragolumab + atezolizumab and placebo + atezolizumab compared with double placebo and the efficacy of tiragolumab + atezolizumab versus placebo + atezolizumab • To evaluate safety and tolerability of tiragolumab + atezolizumab and placebo + atezolizumab compared with double placebo • To characterize pharmacokinetics of tiragolumab and atezolizumab • To evaluate immune response to tiragolumab and atezolizumab. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age >=18 years • Eastern Cooperative Oncology Group Performance Status of 0 or 1 • Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the esophagus • Unresectable locally advanced disease • Definitive concurrent chemoradiation treatment according to regional oncology guidelines for esophageal cancer • Representative archival formalin-fixed, paraffin-embedded tumor specimens, collected prior to initiation of definitive chemoradiotherapy • Adequate hematologic and end-organ function • Women of childbearing potential must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period, for 5 months after the final dose of atezolizumab/placebo, and for 90 days after the final dose of tiragolumab/placebo. • Men must agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm during the treatment period and for 90 days after the final dose of tiragolumab/placebo. |
|
E.4 | Principal exclusion criteria |
• Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-TIGIT therapeutic antibodies • Any unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE) Grade >= 2 from the prior chemoradiation therapy with the exception of irreversible and manageable hearing loss • Prior allogeneic stem cell or solid organ transplantation • Active or history of autoimmune disease or immune deficiency • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis • Malignancy other than esophageal cancer within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death • Treatment with any other investigational agent, including EGFR inhibitors, with therapeutic intent for esophageal cancer prior to randomization. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Progression-Free Survival as determined by the investigator (for tiragolumab + atezolizumab compared with double placebo) 2. Overall survival (for tiragolumab + atezolizumab compared with double placebo) 3. Overall Survival (for placebo + atezolizumab compared with double placebo). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1-3. Up to approximately 50 months. |
|
E.5.2 | Secondary end point(s) |
1. Progression-Free Survival as determined by the investigator (for placebo + atezolizumab compared with double placebo) 2. Overall Survival (for tiragolumab + atezolizumab versus placebo + atezolizumab) 3. Progression-Free Survival as determined by the independent review facility (IRF) 4. Confirmed ORR as determined by the investigator 5. Confirmed ORR as determined by an IRF 6. Duration of response as determined by the investigator 7. Duration of response as determined by the IRF 8. Proportion of patients with clinically meaningful changes in physical functioning, role functioning, global health status/quality of life, and dysphagia, as measured by the respective scales of the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire and the European Organisation for Research and Treatment of Cancer Quality of Life-Esophageal Cancer, Module 18 Questionnaire 9. Incidence and severity of adverse events 10. Serum concentration of tiragolumab and atezolizumab at specified timepoints 11. Prevalence of anti-drug antibody (ADAs) to tiragolumab at baseline and incidence of ADAs to tiragolumab during the study 12. Prevalence of ADAs to atezolizumab at baseline and incidence of ADAs to atezolizumab during the study. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1- 7. Up to approximately 50 months 8. Day 1 of Cycle 1 and Day 1 of every cycle thereafter until treatment discontinuation, and at the study treatment discontinuation visit and during survival follow-up, every 3 months for 1 year 9. Up to approximately 50 months 10-12. Day 1 of Cycle 1, Day 1 of Cycle 2-4, 8, 12, 16 and at treatment discontinuation, disease progression, or completion visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity, Biomarker (exploratory) and Health Status Utility Objective. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 75 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Austria |
Belgium |
Brazil |
Canada |
China |
Czech Republic |
France |
Germany |
Greece |
Hungary |
Israel |
Italy |
Japan |
Korea, Republic of |
New Zealand |
Poland |
Portugal |
Russian Federation |
South Africa |
Spain |
Switzerland |
Taiwan |
Thailand |
Turkey |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 50 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 50 |